BG103278A - Medicamentous treatment - Google Patents

Medicamentous treatment

Info

Publication number: BG103278A
Authority: BG; Bulgaria
Prior art keywords: medicamentous treatment; coronarovascular; hyperuricaemia; gout; monohydrate
Prior art date: 1996-09-25

Application number

BG103278A

Other languages

Bulgarian (bg)

English (en)

Inventor

Peter Kelly

Stephan Jones

Original Assignee

Abbott Gmbh & Co. Kg

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1996-09-25

Filing date

1999-03-24

Publication date

2000-01-31

1999-03-24 Application filed by Abbott Gmbh & Co. Kg filed Critical Abbott Gmbh & Co. Kg

2000-01-31 Publication of BG103278A publication Critical patent/BG103278A/xx

Links

150000001875 compounds Chemical class 0.000 abstract 2
MYGAXIMDAMLUIA-UHFFFAOYSA-N 1-[2-(4-chlorophenyl)cyclobutyl]-n,n,3-trimethylbutan-1-amine;hydrochloride Chemical compound Cl.CC(C)CC(N(C)C)C1CCC1C1=CC=C(Cl)C=C1 MYGAXIMDAMLUIA-UHFFFAOYSA-N 0.000 abstract 1
201000005569 Gout Diseases 0.000 abstract 1
UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 abstract 1
201000001431 Hyperuricemia Diseases 0.000 abstract 1
LEHOTFFKMJEONL-UHFFFAOYSA-N Uric Acid Chemical compound N1C(=O)NC(=O)C2=C1NC(=O)N2 LEHOTFFKMJEONL-UHFFFAOYSA-N 0.000 abstract 1
TVWHNULVHGKJHS-UHFFFAOYSA-N Uric acid Natural products N1C(=O)NC(=O)C2NC(=O)NC21 TVWHNULVHGKJHS-UHFFFAOYSA-N 0.000 abstract 1
201000010099 disease Diseases 0.000 abstract 1
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
229910052739 hydrogen Inorganic materials 0.000 abstract 1
239000001257 hydrogen Substances 0.000 abstract 1
125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 abstract 1
150000004682 monohydrates Chemical class 0.000 abstract 1
150000003839 salts Chemical class 0.000 abstract 1
229940116269 uric acid Drugs 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism

Landscapes

Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Chemical Kinetics & Catalysis (AREA)
Bioinformatics & Cheminformatics (AREA)
Organic Chemistry (AREA)
General Chemical & Material Sciences (AREA)
Epidemiology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Engineering & Computer Science (AREA)
Hematology (AREA)
Diabetes (AREA)
Pain & Pain Management (AREA)
Rheumatology (AREA)
Physical Education & Sports Medicine (AREA)
Urology & Nephrology (AREA)
Obesity (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Materials For Medical Uses (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Crystals, And After-Treatments Of Crystals (AREA)

BG103278A 1996-09-25 1999-03-24 Medicamentous treatment BG103278A (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
GBGB9619962.5A GB9619962D0 (en)	1996-09-25	1996-09-25	Medical treatment
PCT/EP1997/005034 WO1998013033A1 (en)	1996-09-25	1997-09-15	Medical treatment

Publications (1)

Publication Number	Publication Date
BG103278A true BG103278A (en)	2000-01-31

Family

ID=10800448

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
BG103278A BG103278A (en)	1996-09-25	1999-03-24	Medicamentous treatment

Country Status (26)

Country	Link
US (1)	US6162831A (de)
EP (1)	EP1007023B1 (de)
JP (1)	JP2001501608A (de)
KR (1)	KR20000048568A (de)
CN (1)	CN1231604A (de)
AT (1)	ATE239460T1 (de)
AU (1)	AU722129B2 (de)
BG (1)	BG103278A (de)
BR (1)	BR9711414A (de)
CA (1)	CA2266438A1 (de)
DE (1)	DE69721838T2 (de)
DK (1)	DK1007023T3 (de)
ES (1)	ES2199374T3 (de)
GB (1)	GB9619962D0 (de)
HR (1)	HRP970519A2 (de)
HU (1)	HUP9904545A3 (de)
IL (1)	IL128851A (de)
NO (1)	NO991425D0 (de)
NZ (1)	NZ334668A (de)
PL (1)	PL332423A1 (de)
PT (1)	PT1007023E (de)
SK (1)	SK32199A3 (de)
TR (1)	TR199900649T2 (de)
TW (1)	TW415842B (de)
WO (1)	WO1998013033A1 (de)
ZA (1)	ZA978573B (de)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6476078B2 (en)	1999-08-11	2002-11-05	Sepracor, Inc.	Methods of using sibutramine metabolites in combination with a phosphodiesterase inhibitor to treat sexual dysfunction
US6331571B1 (en)	1998-08-24	2001-12-18	Sepracor, Inc.	Methods of treating and preventing attention deficit disorders
US6339106B1 (en)	1999-08-11	2002-01-15	Sepracor, Inc.	Methods and compositions for the treatment and prevention of sexual dysfunction
US6974838B2 (en)	1998-08-24	2005-12-13	Sepracor Inc.	Methods of treating or preventing pain using sibutramine metabolites
BR0009081A (pt) *	1999-03-19	2003-03-05	Knoll Gmbh	Tratamento de osteoartrite
US6552087B1 (en)	1999-03-19	2003-04-22	Abbott Gmbh & Co. Kg	Therapeutic agent comprising (+)-sibutramine
US6399826B1 (en)	1999-08-11	2002-06-04	Sepracor Inc.	Salts of sibutramine metabolites, methods of making sibutramine metabolites and intermediates useful in the same, and methods of treating pain
US6610887B2 (en)	2001-04-13	2003-08-26	Sepracor Inc.	Methods of preparing didesmethylsibutramine and other sibutramine derivatives
US9655932B2 (en) *	2002-03-13	2017-05-23	Kibow Biotech, Inc.	Composition and method for preventing or treating gout or hyperuricemia
US11103542B2 (en)	2002-03-13	2021-08-31	Kibow Biotech, Inc.	Composition and method for maintaining healthy kidney function
PL375032A1 (en) *	2002-10-05	2005-11-14	Hanmi Pharm.Co, Ltd.	Pharmaceutical composition comprising crystalline sibutramine methanesulfonate hemihydrate
US20050131074A1 (en) *	2003-08-04	2005-06-16	Beckman Kristen M.	Methods for treating metabolic syndrome
US8557831B2 (en) *	2004-07-21	2013-10-15	University Of Florida Research Foundation, Inc.	Compositions and methods for treatment and prevention of insulin resistance
KR100627687B1 (ko) *	2005-04-20	2006-09-25	주식회사 씨티씨바이오	시부트라민 유리염기 함유 조성물 및 이의 제조방법
KR20080046601A (ko) *	2006-11-22	2008-05-27	에스케이케미칼주식회사	보관안정성이 우수한 시부트라민 함유 포접복합체
US11179426B2 (en)	2016-12-29	2021-11-23	Kibow Biotech, Inc.	Composition and method for maintaining healthy kidney function
JP2022536222A (ja) *	2018-11-02	2022-08-15	アンパサンドバイオファーマシューティカルズインコーポレイテッド	局所的に施用される緩衝液によるカチオン過負荷および電解質平衡異常のリスクの管理

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
IE52768B1 (en) *	1981-04-06	1988-02-17	Boots Co Ltd	1-arylcyclobutylalkylamine compounds useful as therapeutic agents
GB8531071D0 (en) *	1985-12-17	1986-01-29	Boots Co Plc	Therapeutic compound
GB8704777D0 (en) *	1987-02-28	1987-04-01	Boots Co Plc	Medical treatment
JP2675573B2 (ja) *	1988-03-31	1997-11-12	科研製薬株式会社	脳機能改善剤
IE61928B1 (en) *	1988-11-29	1994-11-30	Boots Co Plc	Treatment of obesity
EP0647134A4 (de) *	1992-06-23	1997-07-30	Sepracor Inc	Verfahren und zusammensetzungen zur behandlung von depression und anderen erkrankungen unter verwendung von optisch-reinem sibutramin.
JPH07508281A (ja) *	1992-06-23	1995-09-14	セプラコア　インコーポレーテッド	光学的に純粋な（＋）シブトラミンを用いるうつ病およびその他の障害を治療する方法ならびに組成物
US5459164A (en) *	1994-02-03	1995-10-17	Boots Pharmaceuticals, Inc.	Medical treatment

1996
- 1996-09-25 GB GBGB9619962.5A patent/GB9619962D0/en active Pending
1997
- 1997-09-15 IL IL12885197A patent/IL128851A/xx not_active IP Right Cessation
- 1997-09-15 BR BR9711414-6A patent/BR9711414A/pt not_active Application Discontinuation
- 1997-09-15 SK SK321-99A patent/SK32199A3/sk unknown
- 1997-09-15 DE DE69721838T patent/DE69721838T2/de not_active Expired - Fee Related
- 1997-09-15 ES ES97942030T patent/ES2199374T3/es not_active Expired - Lifetime
- 1997-09-15 HU HU9904545A patent/HUP9904545A3/hu unknown
- 1997-09-15 EP EP97942030A patent/EP1007023B1/de not_active Expired - Lifetime
- 1997-09-15 PL PL97332423A patent/PL332423A1/xx unknown
- 1997-09-15 TR TR1999/00649T patent/TR199900649T2/xx unknown
- 1997-09-15 NZ NZ334668A patent/NZ334668A/xx unknown
- 1997-09-15 CN CN97198232A patent/CN1231604A/zh active Pending
- 1997-09-15 DK DK97942030T patent/DK1007023T3/da active
- 1997-09-15 AT AT97942030T patent/ATE239460T1/de not_active IP Right Cessation
- 1997-09-15 KR KR1019990702491A patent/KR20000048568A/ko not_active Ceased
- 1997-09-15 JP JP10515217A patent/JP2001501608A/ja active Pending
- 1997-09-15 US US09/269,339 patent/US6162831A/en not_active Expired - Fee Related
- 1997-09-15 PT PT97942030T patent/PT1007023E/pt unknown
- 1997-09-15 CA CA002266438A patent/CA2266438A1/en not_active Abandoned
- 1997-09-15 WO PCT/EP1997/005034 patent/WO1998013033A1/en not_active Ceased
- 1997-09-15 AU AU43851/97A patent/AU722129B2/en not_active Ceased
- 1997-09-25 TW TW086113992A patent/TW415842B/zh not_active IP Right Cessation
- 1997-09-25 ZA ZA978573A patent/ZA978573B/xx unknown
- 1997-09-25 HR HR9619962.5A patent/HRP970519A2/hr not_active Application Discontinuation
1999
- 1999-03-24 NO NO991425A patent/NO991425D0/no unknown
- 1999-03-24 BG BG103278A patent/BG103278A/xx unknown

Also Published As

Publication number	Publication date
EP1007023A1 (de)	2000-06-14
BR9711414A (pt)	2000-04-25
AU722129B2 (en)	2000-07-20
CN1231604A (zh)	1999-10-13
EP1007023B1 (de)	2003-05-07
WO1998013033A1 (en)	1998-04-02
DE69721838D1 (de)	2003-06-12
SK32199A3 (en)	1999-12-10
US6162831A (en)	2000-12-19
HRP970519A2 (en)	1998-08-31
KR20000048568A (ko)	2000-07-25
NO991425L (no)	1999-03-24
IL128851A0 (en)	2000-01-31
HUP9904545A2 (hu)	2000-11-28
NO991425D0 (no)	1999-03-24
IL128851A (en)	2001-08-26
JP2001501608A (ja)	2001-02-06
CA2266438A1 (en)	1998-04-02
ES2199374T3 (es)	2004-02-16
TR199900649T2 (xx)	1999-07-21
GB9619962D0 (en)	1996-11-13
HUP9904545A3 (en)	2000-12-28
AU4385197A (en)	1998-04-17
TW415842B (en)	2000-12-21
DK1007023T3 (da)	2003-08-25
NZ334668A (en)	2000-07-28
PL332423A1 (en)	1999-09-13
DE69721838T2 (de)	2004-01-22
ZA978573B (en)	1999-03-25
ATE239460T1 (de)	2003-05-15
PT1007023E (pt)	2003-08-29

Publication	Publication Date	Title
BG103278A (en)	2000-01-31	Medicamentous treatment
ZA95814B (en)	1995-08-03	Medical treatment
BG103277A (en)	2000-01-31	Application of sibutramine analogues for the prevention of diabetes development
MY127946A (en)	2007-01-31	Therapeutic formulation for administering tolterodine with controlled release
BR0308904A (pt)	2005-05-03	Método de tratamento de gastroparesia, e, uso de um composto de glp-1
NO996108L (no)	2000-02-10	9-oksinerytromycinderivater
GR3005990T3 (de)	1993-06-07
WO2000056315A8 (en)	2001-06-21	Treatment of pain
ZA922910B (en)	1994-01-24	Heterocylic pharmaceutical compounds preparation and use
MXPA01009467A (es)	2004-03-19	Metodo para controlar el aumento de peso asociado con farmacos terapeuticos.
MXPA01009464A (es)	2004-03-19	Metodo para el tratamiento de apnea de sueno.
AP9901474A0 (en)	1999-03-31	Pharmaceutical composition for treating viral diseases.
TW349864B (en)	1999-01-11	Use of N-(pyridinyl)-1H-indol-a-amines for the preparation of a medicament for the treatment of obsessive-compulsive disorders
MXPA03011193A (es)	2004-02-26	Nuevos compuestos utiles en enfermedad de reflujo.
MY133438A (en)	2007-11-30	Morpholinobenzamide salts
ZA877454B (en)	1988-05-25	Therapeutic agent for the treatment of peptic ulcer disease
GR851423B (de)	1985-11-25
MXPA01009468A (es)	2004-03-19	Tratamiento de hipertension pulmonar.
BG106000A (en)	2002-06-28	Treatment of hiatial hernia
AU2001262786A1 (en)	2002-08-28	Use of l-2-oxothiazolidine-4-carboxylic acid for the treatment of type 2 diabetes
RU99108729A (ru)	2001-02-20	Способ лечения